Clinical Observation Of Anti - Fibrosis Combined With Entecavir In The Treatment Of Hepatic Fibrosis Of Blood Stasis And Blood Deficiency

Purpose: By observing the clinical efficacy of Kangxianfang Co-entecavir in treating Liver Fibrosis after Hepatitis B, the type of blood stasis and the deficiency of Qi and blood in TCM Syndrome,attempt to explain the mechanism of Kangxianfang in treating Liver fibrosis after Hepatitis B,thus to seek an effective way in integrative prevention and treatment of liver fibrosis and reducing the incidence of liver cirrhosis,to provide evidence-based of Traditional Chinese Medicine prevention and treatment in chronic hepatitis to cirrhosis.Materials and methods :To selected 60 patients with chronic hepatitis B,randomly assign to two groups:the treatment group with 30 cases and the control group with 30 cases.Patients of the treatment group were treated with entecavir tablets,0.5 mg/times, 1 time/day,meanwhile oral Kangxianfang,of which 1000 ml water were extracted 300 ml,100ml/times,2times/day.While patients of the control group were only treated with entecavir tablets,0.5 mg/times, 1 time/day.Both were observed 48 weeks.The main purpose of the study was to observe the clinical efficacy of Kangxianfang Co-entecavir in treating Liver Fibrosis after Hepatitis B,and the effects on serological markers,ultrasound results,Hepatitis B virus markers and the liver function of Liver fibrosis.Results:(1)Comparing the symptom scores between the two groups after 24 weeks of treatment,the result was a significant difference(p<0.05).Comparing the symptom scores between the two groups after 48 weeks of treatment,the result was asignificant difference(p<0.05).After 48 weeks of treatment,the total effective rate of symptom improvement in patients of treatment group was 90.0%,while the result of the control group was 68.9%.There was a significant difference between the results of the two groups(p<0.05).(2)There was a significant difference between the results of the two groups in the levels of ALT and AST after both the treatment of 24 and 48 weeks(p<0.05).But there was no significant difference between the results of the two groups in the levels of ALB during the whole treatment(p>0.05).(3)There was a significant difference between the results of the two groups in the levels of HA,LN and IV-C after treatment of 48 weeks(p<0.05).While there was no significant difference between the results of the two groups in the levels of P-III-P after treatment of 48 weeks(p>0.05).(4)There was no significant difference between the results of the two groups in the negative conversion rate of HBe Ag and HBV-DNA after treatment of 48 weeks(p>0.05).(5)After treatment of 48 weeks,the ultrasound results indicated that there was no significant difference between the treatment goup and control group in the inner diameter of portal venous and thickness of the Spleen(p>0.05).(6)After 48 weeks of treatment,the total effective rate of the treatment goup was 86.7%,while the result of control group was 69.0%.There was a significant difference between the results of the groups.Conclusions 1、The treatment of using Kangxianfang Co-entecavir in Liver Fibrosis after Hepatitis B can obviously restrain the reproduction of HBVDNA.Comparing with the treatment of only using entecavir,it has unique advantages in improving symptoms,promoting the liver function to return to normal levels and restraining the Liver Fibrosis.2、The treatment of using Kangxianfang can obviously improve the clinical symptoms of the patients with Liver Fibrosis after Hepatitis B,and it has certain effects of protecting the liver,inhibiting inflammation and anti-fibrosis.